Sponsored

Dr Kelly's team synthesized a PDC series of PDCs designed to treat pulmonary fibrosis precisely, combining the kinase inhibitor nintedanib with a mimetic peptide chain targeting the αVβ6 integrin. Their antifibrotic activity is currently being evaluated in a mouse model of pulmonary fibrosis.
Recent Updates
More Stories
Sponsored


Don't forget, ads time: PentaVerge | AQU | Debwan | ICICTE | Nasseej | ESol | OUST | CorpSNet | PoemsBook | TopDeals | TheReaderView